BioWorld

Feb. 13, 2006

Acorda’s Second Attempt At IPO Successful: $33M

Acorda Therapeutics Inc. priced a $33 million initial public offering Friday, selling 5.5 million common shares at $6 apiece. (BioWorld Today) Read More

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Deal Terms Reward Products: No Surprise From 2005 Trends

Black Box Warning Labels To Remain On All NSAIDs

After First Product Approval, BioMimetic Seeks $50M IPO

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...